# EDGAR Filing Document

**Accession Number:** 0001752828
**File Stem:** 0000000000-25-011802
**Filing Date:** 2025-12
**Character Count:** 2267
**Document Hash:** 81fb39a012c0c0b8bb0b051597b779f0
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000000000-25-011802.hdr.sgml**: 20260701

**ACCESSION NUMBER**: 0000000000-25-011802

**CONFORMED SUBMISSION TYPE**: UPLOAD

**PUBLIC DOCUMENT COUNT**: 2

**FILED AS OF DATE**: 20251223

**FILED FOR**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Celularity Inc
- **CENTRAL INDEX KEY:** 0001752828
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 831702591
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** UPLOAD
- **SEC FILE NUMBER:** 333-292288

**BUSINESS ADDRESS:**
- **STREET 1:** 170 PARK AVE
- **CITY:** FLORHAM PARK
- **STATE:** NJ
- **ZIP:** 07932
- **BUSINESS PHONE:** (908) 768-2170

**MAIL ADDRESS:**
- **STREET 1:** 170 PARK AVE
- **CITY:** FLORHAM PARK
- **STATE:** NJ
- **ZIP:** 07932

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** GX Acquisition Corp.
- **DATE OF NAME CHANGE:** 20180912
**PUBLIC REFERENCE ACCESSION NUMBER**: 0001493152-25-028562

## Text-Extract

```

                                                           December 23, 2025

Robert J. Hariri, M.D., Ph.D.
Chief Executive Officer and Chairman
Celularity Inc.
170 Park Avenue
Florham Park, New Jersey 07932

        Re: Celularity Inc.
            Registration Statement on Form S-1
            Filed December 19, 2025
            File No. 333-292288
Dear Robert J. Hariri M.D., Ph.D.:

       This is to advise you that we have not reviewed and will not review your
registration
statement.

        Please refer to Rules 460 and 461 regarding requests for acceleration.
We remind you
that the company and its management are responsible for the accuracy and
adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action
by the staff.

       Please contact Chris Edwards at 202-551-6761 with any questions.

                                                           Sincerely,

                                                           Division of
Corporation Finance
                                                           Office of Life
Sciences
cc:   Nazia J. Khan, Esq.

```

### Attached PDF Documents

**Attachment 1:** `filename1`

_No text found in this document._